ANI Pharmaceuticals, Inc.
ANIP
$82.10
-$0.58-0.70%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 826.88M | 747.40M | 674.07M | 614.38M | 555.46M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 826.88M | 747.40M | 674.07M | 614.38M | 555.46M |
| Cost of Revenue | 324.55M | 294.23M | 274.09M | 250.21M | 220.13M |
| Gross Profit | 502.34M | 453.17M | 399.98M | 364.17M | 335.33M |
| SG&A Expenses | 302.97M | 295.99M | 263.84M | 236.24M | 211.18M |
| Depreciation & Amortization | 91.40M | 84.52M | 75.94M | 67.73M | 60.33M |
| Other Operating Expenses | -- | 2.54M | 2.66M | 2.66M | 2.66M |
| Total Operating Expenses | 774.97M | 731.15M | 661.16M | 601.41M | 532.09M |
| Operating Income | 51.91M | 16.25M | 12.91M | 12.96M | 23.37M |
| Income Before Tax | 50.55M | -14.75M | -27.56M | -22.21M | -7.50M |
| Income Tax Expenses | 9.98M | -4.54M | -6.51M | -3.69M | -412.00K |
| Earnings from Continuing Operations | 40.57 | -10.21 | -21.05 | -18.52 | -7.09 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 40.57M | -10.21M | -21.05M | -18.52M | -7.09M |
| EBIT | 51.91M | 16.25M | 12.91M | 12.96M | 23.37M |
| EBITDA | 143.31M | 100.77M | 88.85M | 80.69M | 83.69M |
| EPS Basic | 1.70 | -0.75 | -1.16 | -1.02 | -0.44 |
| Normalized Basic EPS | 0.93 | -0.09 | -0.22 | -0.19 | 0.20 |
| EPS Diluted | 1.63 | -0.77 | -1.18 | -1.04 | -0.45 |
| Normalized Diluted EPS | 0.89 | -0.11 | -0.23 | -0.19 | 0.19 |
| Average Basic Shares Outstanding | 78.96M | 78.29M | 77.78M | 77.27M | 76.83M |
| Average Diluted Shares Outstanding | 80.89M | 79.20M | 78.22M | 77.59M | 77.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 3.85% | -15.91% | -7.72% | -8.77% | -22.92% |